Abstract
Danazol, a synthetic androgen reported to increase factor VIII and IX activity levels, was given to 5 hemophiliacs who were >17 years old (3 with severe hemophilia A, one moderate hemophilia A and one moderate hemophilia B). With danazol therapy (600 mg/da) the PTTs shortened 20-30% of pre-treatment times. The prothrombin times and activity levels of factors VIII, IX, and XII did not change during the study period. Addition of plasma from danazol-treated patients to plasma with a known factor VIII inhibitor and to plasma from an untreated severe hemophiliac A patient caused a similar shortening of the respective PTTs. A typical mixing experiment is shown in the Table (IP=inhibitor plasma; NP=normal plasma; HP=hemophilia A control; HP-D=danazol plasma in hemophilia A. The PTTs, in secs, are shown using 1 vol to 1 vol mixing, incubating for 4 min @ 37°C).
Absorption of the danazol plasma with precipitating antibody against factor VIII and IX did not remove the PTT correcting principal. The data suggest that danazol may cause the de novo appearance of an intrinsic coagulation pathway activator having factor VIII and IX bypassing activity.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corrigan, J., Garewal, H., Durie, B. et al. DANAZOL-INDUCED FACTOR IX AND VIII BYPASSING ACTIVITY. Pediatr Res 18 (Suppl 4), 238 (1984). https://doi.org/10.1203/00006450-198404001-00872
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-00872